Carson Michael J.
Transaction: 08/03/2026
BUY
Change
+30,000
Price
Not reported
Filing
08/05/2026
Type
BUY
Nuvectis Pharma, Inc.
NVCT • Biotechnology
$20.59
▲ +1.65 (+8.71%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$483.37M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 2.38Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 1:10 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$20.59
Change8.71%
Shares Out23.48M
Market Cap$483.37M
Enterprise Value$461.21M
52W Range5.55 - 29.27
Beta-0.25
P/E-17.36
P/B53.22
P/FCF-24.78
EV/EBITDA-21.23
EV/FCF-23.64
Price$20.59
Change8.71%
Shares Out23.48M
Market Cap$483.37M
Enterprise Value$461.21M
52W Range5.55 - 29.27
Beta-0.25
P/E-17.36
P/B53.22
P/FCF-24.78
EV/EBITDA-21.23
EV/FCF-23.64
Earnings Yield-5.76%
FCF Yield-4.04%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio2.38
Quick Ratio2.38
Target$37.33
Target Upside81.30%
Target Median$39.00
Target Range33.00 - 40.00
Volume219.85K
Avg Volume272.89K
EPS Surprise0.04
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
29/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 2.38Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 3 analyst votes · 2026-10-21
100/100
Bullish
Bullish
3
Hold
0
Bearish
0
Price Target
2026-08-06
Low
$33.00
Mean
$36.00
Median
$36.00
High
$39.00
Insider Transactions
Recent executive and insider activity
BENTSUR RON
Transaction: 06/30/2026
BUY
Change
+12,500
Price
$20.00
Filing
07/01/2026
Type
BUY
Mosseri Marlio Charles
Transaction: 06/30/2026
BUY
Change
+50,000
Price
$18.32
Filing
07/01/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Carson Michael J. | BUY | +30,000 | Not reported | 08/03/2026 | 08/05/2026 |
| BENTSUR RON | BUY | +12,500 | $20.00 | 06/30/2026 | 07/01/2026 |
| Mosseri Marlio Charles | BUY | +50,000 | $18.32 | 06/30/2026 | 07/01/2026 |
| Kaplan Matthew L. | BUY | +35,000 | Not reported | 06/11/2026 | 06/12/2026 |
| Sanchez Juan | BUY | +35,000 | Not reported | 06/11/2026 | 06/12/2026 |
| Oliviero James F III | BUY | +35,000 | Not reported | 06/11/2026 | 06/12/2026 |
| Hoberman Kenneth | BUY | +35,000 | Not reported | 06/11/2026 | 06/12/2026 |
| Carson Michael J. | BUY | +61,200 | Not reported | 01/06/2026 | 01/09/2026 |
| Poradosu Enrique | BUY | +150,000 | Not reported | 01/06/2026 | 01/09/2026 |
| BENTSUR RON | BUY | +150,000 | Not reported | 01/06/2026 | 01/09/2026 |
| Shemesh Shay | BUY | +150,000 | Not reported | 01/06/2026 | 01/09/2026 |
| Kaplan Matthew L. | BUY | +11,000 | $5.84 | 11/05/2025 | 11/06/2025 |
| Sanchez Juan | BUY | +13,000 | $5.79 | 11/05/2025 | 11/06/2025 |
| BENTSUR RON | BUY | +5,000 | $5.72 | 11/05/2025 | 11/06/2025 |
| Sanchez Juan | OTHER | 0 | Not reported | 09/22/2025 | 10/31/2025 |
| Mosseri Marlio Charles | BUY | +72,836 | $6.28 | 10/27/2025 | 10/29/2025 |
| Mosseri Marlio Charles | BUY | +35,034 | $6.15 | 10/24/2025 | 10/29/2025 |
| Mosseri Marlio Charles | BUY | +46,900 | $6.06 | 10/23/2025 | 10/29/2025 |
| Mosseri Marlio Charles | BUY | +5,603 | $7.99 | 06/20/2025 | 06/24/2025 |
| Mosseri Marlio Charles | BUY | +28,043 | $8.05 | 06/18/2025 | 06/20/2025 |